Back to top

GNC Holdings Global Business Strong, Same Store Sales Weak

Read MoreHide Full Article

On Dec 17, 2018, we issued an updated research report on GNC Holdings, Inc. (GNC - Free Report) . We are upbeat about this Zacks Rank #3 (Hold) company’s significant progress with e-commerce business over the last few quarters. However, cut-throat competition is a persistent concern.

This leading global specialty retailer of products for health and wellness including vitamins, minerals and herbal supplement plus sports nutrition and diet has underperformed its industry in the past year. The stock has plunged 46.7% against the industry's 13.7% growth.

Notably, GNC Holdings exited the third quarter of 2018 on a mixed note with earnings lagging the Zacks Consensus Estimate while revenues exceeding the mark. However, both metrics declined year over year, which is dampening to the stock.

In the third quarter of 2018, revenues decreased 5.4% year over year. This downside was primarily attributable to the sale of LuckyVitamin in September 2017 (this resulted in a $20.8-million reduction in revenues) and lower sales associated with store closures at the end of the respective lease term, a component of the company's store portfolio optimization strategy.

 

Within same store, the company performed disappointingly in domestic franchise locations. Revenues from U.S. & Canada segment contracted 3.2% on the impact of company-owned net store closures, which induced a $9-million decline in revenues, and negative same store sales of 2.1% that caused a revenue decrease of $7.7 million. 

Additionally, domestic franchise revenues deteriorated $3.6 million due to weak retail same store sales and less franchise stores. Although the company is focusing on its ‘New GNC’ plans pertaining to new products and pricing at stores, any immediate improvement is still quite uncertain.

On a positive note, GNC Holdings made major changes in e-commerce pricing and promotion strategy in August 2016. This in turn, eliminated channel conflict and bulk sales. Further, these alterations allowed the company to launch its entire product line on Amazon (sales from the same are included in the GNC.com business unit) in January 2017. Per management, the e-commerce business consistently grows ahead of expectations.

Moreover, the company is optimistic about the website’s shift of control from a third party to a cloud-based, company-controlled platform. This offers the company more flexibility and control over new features and enhancements including advanced personalization capability, improved merchandising and opportunity for omnichannel expansion.

The company’s expanding international business has also been a major plus. Revenues at the international segment increased 6.1% in the reported quarter, driven by higher cross-border e-commerce sales in China and India. Per the company, the Guardian Healthcare Services Pvt. Ltd, its new partner in India, is extending distribution through additional channels like pharmacy, fitness centers and e-commerce.

Lately in China, GNC Holdings entered into a joint venture agreement with Harbin Pharmaceutical Group Holding (Hayao). The company expects its Chinese business revenues to reach a value of $200 million over the next three years. 

Moreover, GNC Holdings’ business is particularly subject to changing consumer trends and preferences. So the company’s steady success depends partly on its ability to anticipate and respond to changes.

Key Picks

Some better-ranked stocks in the broader medical space are Veeva Systems (VEEV - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Surmodics, Inc. (SRDX - Free Report) .

Veeva Systems’ long-term earnings growth rate is estimated at 19.5%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Integer Holdings has an expected earnings growth rate of 30.3% for 2018 and a Zacks Rank of 1.

Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank #2 (Buy).

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>

Published in